Abstract
Darvadstrocel (Alofisel) – indicated for the treatment of complex perianal fistulas caused by Crohn's disease – is the first allogeneic stem‐cell therapy to be approved in the EU. This article examines its administration, efficacy and place in therapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
